With rising Nontuberculous Mycobacteria (NTM) incidence rates and a lack of effective diagnostic tests, vaccines and immunotherapies, pulmonary NTM disease is of increasing concern worldwide.

In support of the search for new therapies for NTM diseases, Johnson & Johnson Innovation is proud to announce that Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has entered into a research collaboration with clinical-stage biopharmaceutical company and Johnson & Johnson Innovation – JLABS @ Shanghai resident company, TenNor Therapeutics (Suzhou) Limited.

Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222044/

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com